These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15711832)

  • 1. Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers.
    Valle M; Barbanoj MJ; Donner A; Izquierdo I; Herranz U; Klein N; Eichler HG; Müller M; Brunner M
    Eur J Clin Pharmacol; 2005 Apr; 61(2):103-11. PubMed ID: 15711832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: a randomized, open-label, multiple dose, crossover study.
    Park SM; Lee J; Seong SJ; Park JG; Gwon MR; Lim MS; Lee HW; Yoon YR; Yang DH; Kwon KI; Han S
    BMC Pharmacol Toxicol; 2014 Dec; 15():75. PubMed ID: 25534747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose.
    Ramis J; Mis R; Forn J; Torrent J; Gorina E; Jané F
    Eur J Drug Metab Pharmacokinet; 1991; 16(4):269-73. PubMed ID: 1823870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers.
    Quetglas EG; Campanero MA; Sádaba B; Escolar M; Azanza JR
    Arzneimittelforschung; 2008; 58(6):283-7. PubMed ID: 18677970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects.
    Ge J; Ding LK; Yang J; Jia YY; Lu CT; Ding Y; Song Y; Song W; Wen AD
    Int J Clin Pharmacol Ther; 2015 Mar; 53(3):272-6. PubMed ID: 25546165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of triflusal and its main metabolite in rats and dogs.
    Ramis J; Mis R; Forn J
    Eur J Drug Metab Pharmacokinet; 1991; 16(4):261-8. PubMed ID: 1823869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects.
    Wang M; Zhang Q; Huang M; Zong S; Hua W; Zhou W
    Drug Res (Stuttg); 2014 May; 64(5):263-8. PubMed ID: 24105106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effect of triflusal and its main metabolite HTB in an in vitro model of anoxia-reoxygenation in rat brain slices: comparison with acetylsalicylic and salicylic acids.
    González-Correa JA; Arrebola MM; Ureña IM; Ruiz-Villafranca D; Muñoz-Marín J; Guerrero A; Sánchez de la Cuesta F; De La Cruz JP
    Naunyn Schmiedebergs Arch Pharmacol; 2005 Jan; 371(1):81-8. PubMed ID: 15602657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative bioavailability study of triflusal oral solution vs. triflusal capsules in healthy subjects. A single, randomized, two-way cross-over, open-label phase I study.
    Izquierdo I; Borja J; Rovira S; Pelagio P; Torres F; Cebrecos J; García-Rafanell J
    Arzneimittelforschung; 2010; 60(1):36-41. PubMed ID: 20184225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of triflusal after single and repeated doses in man.
    Ramis J; Torrent J; Mis R; Conte L; Barbanoj MJ; Jané J; Forn J
    Int J Clin Pharmacol Ther Toxicol; 1990 Aug; 28(8):344-9. PubMed ID: 2272716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study to characterize the multiple-dose pharmacokinetics, pharmacodynamics and safety of new enteric-coated triflusal formulations in healthy male volunteers.
    Lee HW; Lim MS; Seong SJ; Lee J; Park J; Seo JJ; Yun HY; Baek IH; Kwon KI; Yoon YR
    Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1471-9. PubMed ID: 22098139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous determination of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in rat and human plasma by high-performance liquid chromatography.
    Cho HY; Jeong TJ; Lee YB
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Dec; 798(2):257-64. PubMed ID: 14643505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet antiaggregatory effect of triflusal in human whole blood.
    de la Cruz JP; Pavia J; Bellido I; González MC; Sánchez de la Cuesta F
    Methods Find Exp Clin Pharmacol; 1988 Apr; 10(4):273-7. PubMed ID: 3386335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of a metabolite of triflusal (2-hydroxy-4-trifluoromethylbenzoic acid) to serum proteins in rat and man.
    Mis R; Ramis J; Conte L; Forn J
    Eur J Clin Pharmacol; 1992; 42(2):175-9. PubMed ID: 1618249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid.
    Fernández de Arriba A; Cavalcanti F; Miralles A; Bayón Y; Alonso A; Merlos M; García-Rafanell J; Forn J
    Mol Pharmacol; 1999 Apr; 55(4):753-60. PubMed ID: 10101034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective effect of triflusal and its main metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid (HTB), in the postischemic brain.
    Kim SW; Choi KJ; Park JY; Yoon SH; Lee JK
    Neurosci Lett; 2017 Mar; 643():59-64. PubMed ID: 28189746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic Study of Triflusal in Elderly Subjects After Single and Repeated Oral Administration.
    Ferrari E; Reboldi G; Marenco P; D'Angelo L; Crema F; Ambrosoli L; Poli A; Girardello R; Lowenthal DT
    Am J Ther; 1996 Sep; 3(9):630-636. PubMed ID: 11862303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of triflusal and its main metabolite HTB on platelet interaction with subendothelium in healthy volunteers.
    De La Cruz JP; Villalobos MA; García PJ; Smith-Agreda JM; Sánchez de la Cuesta F
    Eur J Clin Pharmacol; 1995; 47(6):497-502. PubMed ID: 7768251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro protein binding interaction between a metabolite of triflusal, 2-hydroxy-4-trifluoromethylbenzoic acid and other drugs.
    Mis R; Ramis J; Conte L; Forn J
    J Pharm Pharmacol; 1992 Nov; 44(11):935-7. PubMed ID: 1361542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effects of triflusal on secondary thrombus growth and vascular cyclooxygenase-2.
    Duran X; Sánchez S; Vilahur G; Badimon L
    J Thromb Haemost; 2008 Aug; 6(8):1385-92. PubMed ID: 18503633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.